BALTIMORE , Aug. 27, 2024 /PRNewswire/ -- Sysmex Inostics Inc., a subsidiary of Japan's Sysmex Corporation and Baltimore -based biotechnology firm and CLIA-certified lab, in collaboration with the University of Chicago Medicine announces the publication of results from the OPTIMAII trial in JAMA Oncology .
Circulating tumor HPV-DNA (ctHPV-DNA) clearance, monitored using HPV-SEQ assay, predicts improved survival in patients with HPV-associated oropharyngeal cancer following nivolumab-based neoadjuvant therapy. "At Sysmex Inostics, we recognize the critical role of ctHPV-DNA monitoring in accelerating drug development and ultimately optimizing patient care and treatment management for HPV-driven cancers," said Shinichi Sato , President, and CEO of Sysmex Inostics. "We are excited about the latest findings using HPV-SEQ published in JAMA Oncology .
These collaborative efforts with academia and pharma attest to our commitment in expediting the use of this novel biomarker in clinical settings," said Sato. This is the first clinical trial to assess immunotherapy (nivolumab) in the neoadjuvant chemotherapy setting with response-adapted deintensification therapy. Non-invasive biomarkers such as PDL-1 and ctHPV-DNA were assessed pre/post-treatment to understand their clinical utility in treatment monitoring and surveillance, especially as a future tool to guide treatment strategy for treatment de-intensification.
Key results from the study include: All (31, 100%) patients with paired .